Elaine T. Alarid
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Elaine T. Alarid has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
Amy M. Fowler
Department of Physiology, University of Wisconsin—Madison, Madison, Wisconsin 53706,1 Equipe d'Endocrinologie Moléculaire de la Reproduction (EMR), Universite de Rennes I, 35042 Rennes Cedex, France2
3 shared publicationsNatalia M. Solodin
Department of Physiology, University of Wisconsin—Madison, Madison, Wisconsin 53706,1 Equipe d'Endocrinologie Moléculaire de la Reproduction (EMR), Universite de Rennes I, 35042 Rennes Cedex, France2
2 shared publicationsAdrian V. Lee
The Breast Center and Department of Medicine Baylor College of Medicine Houston Texas USA
1 shared publicationChristopher C. Valley
Department of Physiology, 1300 University Ave., 120 SMI, University of Wisconsin--Madison, Madison, Wisconsin 53706, USA
1 shared publicationLindsay Hill
Department of Physiology, University of Wisconsin—Madison, Madison, Wisconsin 53706,1 Equipe d'Endocrinologie Moléculaire de la Reproduction (EMR), Universite de Rennes I, 35042 Rennes Cedex, France2
1 shared publicationMara T. Mashek
Department of Physiology, University of Wisconsin—Madison, Madison, Wisconsin 53706,1 Equipe d'Endocrinologie Moléculaire de la Reproduction (EMR), Universite de Rennes I, 35042 Rennes Cedex, France2
1 shared publication
Latest Publications
- Open Access
- 1 September 2006
- Published by The Endocrine Society in Molecular Endocrinology
- Vol. 20 (9) , 1972-1981
Lives and Times of Nuclear Receptors
Down-regulation of receptor in response to ligand was one of the earliest functional readouts of steroid hormone action. The loss of total receptor content upon stimulation, referred to initially as receptor “processing,” was carefully described with respect to receptor nuclear transformation or tight nuclear binding. It was these early studies that were the first to note a correlation between receptor turnover and induction of gene transcription, leading to the proposal that down-regulation of receptor was involved in mechanisms of transcriptional activation. This idea has now attracted renewed attention with the discovery that ligand-induced “processing” in the form of proteolysis is carried out by the 26S proteasome, a multicatalytic enzyme whose activity is directly coupled to cell-cycle control, signal transduction, and importantly, transcription. Here, we review our current understanding of the mechanism and relevance of proteolysis to receptor function based on general concepts that have emerged from analyses of liganded members of the nuclear receptor family.
- 1 September 2006
- Published by The Endocrine Society in Molecular Endocrinology
- Vol. 20 (9) , 1972-1981
Open AccessLives and Times of Nuclear Receptors
Down-regulation of receptor in response to ligand was one of the earliest functional readouts of steroid hormone action. The loss of total receptor content upon stimulation, referred to initially as receptor “processing,” was carefully described with respect to receptor nuclear transformation or tight nuclear binding. It was these early studies that were the first to note a correlation between receptor turnover and induction of gene transcription, leading to the proposal that down-regulation of receptor was involved in mechanisms of transcriptional activation. This idea has now attracted renewed attention with the discovery that ligand-induced “processing” in the form of proteolysis is carried out by the 26S proteasome, a multicatalytic enzyme whose activity is directly coupled to cell-cycle control, signal transduction, and importantly, transcription. Here, we review our current understanding of the mechanism and relevance of proteolysis to receptor function based on general concepts that have emerged from analyses of liganded members of the nuclear receptor family.
- 1 July 2005
- Published by Taylor & Francis in Molecular and Cellular Biology
- Vol. 25 (13) , 5417-5428
Differential Regulation of Estrogen-Inducible Proteolysis and Transcription by the Estrogen Receptor α N Terminus
The ubiquitin-proteasome pathway has emerged as an important regulatory mechanism governing the activity of several transcription factors. While estrogen receptor α (ERα) is also subjected to rapid ubiquitin-proteasome degradation, the relationship between proteolysis and transcriptional regulation is incompletely understood. Based on studies primarily focusing on the C-terminal ligand-binding and AF-2 transactivation domains, an assembly of an active transcriptional complex has been proposed to signal ERα proteolysis that is in turn necessary for its transcriptional activity. Here, we investigated the role of other regions of ERα and identified S118 within the N-terminal AF-1 transactivation domain as an additional element for regulating estrogen-induced ubiquitination and degradation of ERα. Significantly, different S118 mutants revealed that degradation and transcriptional activity of ERα are mechanistically separable functions of ERα. We find that proteolysis of ERα correlates with the ability of ERα mutants to recruit specific ubiquitin ligases regardless of the recruitment of other transcription-related factors to endogenous model target genes. Thus, our findings indicate that the AF-1 domain performs a previously unrecognized and important role in controlling ligand-induced receptor degradation which permits the uncoupling of estrogen-regulated ERα proteolysis and transcription.
- 1 July 2005
- Published by Taylor & Francis in Molecular and Cellular Biology
- Vol. 25 (13) , 5417-5428
Differential Regulation of Estrogen-Inducible Proteolysis and Transcription by the Estrogen Receptor α N Terminus
The ubiquitin-proteasome pathway has emerged as an important regulatory mechanism governing the activity of several transcription factors. While estrogen receptor α (ERα) is also subjected to rapid ubiquitin-proteasome degradation, the relationship between proteolysis and transcriptional regulation is incompletely understood. Based on studies primarily focusing on the C-terminal ligand-binding and AF-2 transactivation domains, an assembly of an active transcriptional complex has been proposed to signal ERα proteolysis that is in turn necessary for its transcriptional activity. Here, we investigated the role of other regions of ERα and identified S118 within the N-terminal AF-1 transactivation domain as an additional element for regulating estrogen-induced ubiquitination and degradation of ERα. Significantly, different S118 mutants revealed that degradation and transcriptional activity of ERα are mechanistically separable functions of ERα. We find that proteolysis of ERα correlates with the ability of ERα mutants to recruit specific ubiquitin ligases regardless of the recruitment of other transcription-related factors to endogenous model target genes. Thus, our findings indicate that the AF-1 domain performs a previously unrecognized and important role in controlling ligand-induced receptor degradation which permits the uncoupling of estrogen-regulated ERα proteolysis and transcription.
- 7 December 2004
- Published by American Association for the Advancement of Science (AAAS) in Science's STKE
- Vol. 2004 (262) , tr11
Nuclear Receptor and Transcriptional Complex Cycles
Transcriptional regulation by ligand-activated nuclear receptors, also known as steroid receptors, is a highly dynamic process. Nuclear receptors are intracellular proteins that reside in either the cytoplasm or nucleus in the inactive state. The interaction of this family of receptors with the promoters of target genes and with various proteins involved in stimulating gene expression is governed by binding to lipid soluble ligands. The animation, based on experiments following the dynamic interactions of the glucocorticoid receptor or the estrogen receptor with DNA, shows nuclear estrogen receptor and its interaction with a short two-nucleosome fragment of chromatin in the absence and presence of estrogen. The events that occur on the DNA are represented by the ordered recruitment of protein components to a larger macromolecular complex. The associated table describes the proteins and multimolecular complexes that participate in the nuclear receptor-chromatin cycles.
- 7 December 2004
- Published by American Association for the Advancement of Science (AAAS) in Science's STKE
- Vol. 2004 (262) , tr11
Nuclear Receptor and Transcriptional Complex Cycles
Transcriptional regulation by ligand-activated nuclear receptors, also known as steroid receptors, is a highly dynamic process. Nuclear receptors are intracellular proteins that reside in either the cytoplasm or nucleus in the inactive state. The interaction of this family of receptors with the promoters of target genes and with various proteins involved in stimulating gene expression is governed by binding to lipid soluble ligands. The animation, based on experiments following the dynamic interactions of the glucocorticoid receptor or the estrogen receptor with DNA, shows nuclear estrogen receptor and its interaction with a short two-nucleosome fragment of chromatin in the absence and presence of estrogen. The events that occur on the DNA are represented by the ordered recruitment of protein components to a larger macromolecular complex. The associated table describes the proteins and multimolecular complexes that participate in the nuclear receptor-chromatin cycles.
- Open Access
- 1 January 2004
- Published by Wiley in The FASEB Journal
- Vol. 18 (1) , 81-93
Increases in estrogen receptor‐α concentration in breast cancer cells promote serine 118/104/106‐independent AF‐1 transactivation and growth in the absence of estrogen
A common phenotype in breast cancer is the expansion of the estrogen receptor‐α (ER+) cell population and an inappropriate elevation of ERα protein, the latter predisposing patients for a poorer prognosis than those with lower levels of the receptor. A tetracycline‐inducible ERα overexpression model was developed in the MCF‐7 cell line to assess induction of endogenous gene activation and growth in response to elevations in ERα protein. Heightened levels of ERα resulted in aberrant promoter occupancy and gene activation in the absence of hormone, which was independent of ligand and AF‐2 function. This increased receptor activity required the amino‐terminal A/B domain and was not inhibited by tamoxifen, which supports an enhancement of AF‐1 function, yet was independent of serine‐104, 106, and 118 phosphorylation. Ligand‐independent transcription was accompanied by an increase in growth in the absence of hormonal stimulation. The results suggest that elevated levels of ERα in breast cancer cells can result in activation of receptor transcriptional function in a manner distinct from classical mechanisms that involve ligand binding or growth factor‐induced phosphorylation. Further, they describe a potential mechanism whereby increases in ERα concentration may provide a proliferative advantage by augmenting ERα function regardless of ligand status.—Fowler, A. M., Solodin, N., Preisler‐Mashek, M. T., Zhang, P., Lee, A. V., Alarid, E. T. Increases in estrogen receptor‐α concentration in breast cancer cells promote serine 118/104/106‐independent AF‐1 transactivation and growth in the absence of estrogen. FASEB J. 18, 81–93 (2004)
- 1 January 2004
- Published by Wiley in The FASEB Journal
- Vol. 18 (1) , 81-93
Open AccessIncreases in estrogen receptor‐α concentration in breast cancer cells promote serine 118/104/106‐independent AF‐1 transactivation and growth in the absence of estrogen
A common phenotype in breast cancer is the expansion of the estrogen receptor‐α (ER+) cell population and an inappropriate elevation of ERα protein, the latter predisposing patients for a poorer prognosis than those with lower levels of the receptor. A tetracycline‐inducible ERα overexpression model was developed in the MCF‐7 cell line to assess induction of endogenous gene activation and growth in response to elevations in ERα protein. Heightened levels of ERα resulted in aberrant promoter occupancy and gene activation in the absence of hormone, which was independent of ligand and AF‐2 function. This increased receptor activity required the amino‐terminal A/B domain and was not inhibited by tamoxifen, which supports an enhancement of AF‐1 function, yet was independent of serine‐104, 106, and 118 phosphorylation. Ligand‐independent transcription was accompanied by an increase in growth in the absence of hormonal stimulation. The results suggest that elevated levels of ERα in breast cancer cells can result in activation of receptor transcriptional function in a manner distinct from classical mechanisms that involve ligand binding or growth factor‐induced phosphorylation. Further, they describe a potential mechanism whereby increases in ERα concentration may provide a proliferative advantage by augmenting ERα function regardless of ligand status.—Fowler, A. M., Solodin, N., Preisler‐Mashek, M. T., Zhang, P., Lee, A. V., Alarid, E. T. Increases in estrogen receptor‐α concentration in breast cancer cells promote serine 118/104/106‐independent AF‐1 transactivation and growth in the absence of estrogen. FASEB J. 18, 81–93 (2004)
- 1 August 2003
- Published by The Endocrine Society in Endocrinology
- Vol. 144 (8) , 3469-3476
Thyroid Hormone Is an Inhibitor of Estrogen-Induced Degradation of Estrogen Receptor-α Protein: Estrogen-Dependent Proteolysis Is Not Essential for Receptor Transactivation Function in the Pituitary
Proteolysis by the 26S proteasome is an important regulatory mechanism that governs the protein stability of several steroid/nuclear receptors and that has been implicated in the control of receptor transcriptional activation function. Herein, we report that thyroid hormone can prevent estrogen-induced proteolysis of estrogen receptor-alpha (ERalpha) protein in lactotrope cells of the pituitary. The stabilization of ERalpha protein by thyroid hormone represents a selective blockade against estradiol-stimulated degradation, because thyroid hormone (but not glucocorticoid) can protect estrogen-activated ERalpha. Moreover, thyroid hormone treatment does not interfere with signal-induced proteolysis of a separate proteasome target, IkappaBalpha or ERalpha proteolysis induced by ICI182780. Using thyroid hormone as a tool to inhibit ERalpha proteolysis, we examined the effect of loss of this regulatory function on estrogen-induced transcriptional responses. Consistent with earlier reports, estrogen activation of an idealized estrogen response element reporter gene was inhibited. However, thyroid hormone did not prevent induction of prolactin gene expression or the ability of ERalpha to stimulate proliferation. These results demonstrate that estrogen-induced proteolysis of ERalpha is not a general requirement for receptor transcriptional activation function, and they demonstrate that proteolytic regulation is a means by which other endocrine factors can indirectly modulate ERalpha activity.
- 1 August 2003
- Published by The Endocrine Society in Endocrinology
- Vol. 144 (8) , 3469-3476
Thyroid Hormone Is an Inhibitor of Estrogen-Induced Degradation of Estrogen Receptor-α Protein: Estrogen-Dependent Proteolysis Is Not Essential for Receptor Transactivation Function in the Pituitary
Proteolysis by the 26S proteasome is an important regulatory mechanism that governs the protein stability of several steroid/nuclear receptors and that has been implicated in the control of receptor transcriptional activation function. Herein, we report that thyroid hormone can prevent estrogen-induced proteolysis of estrogen receptor-alpha (ERalpha) protein in lactotrope cells of the pituitary. The stabilization of ERalpha protein by thyroid hormone represents a selective blockade against estradiol-stimulated degradation, because thyroid hormone (but not glucocorticoid) can protect estrogen-activated ERalpha. Moreover, thyroid hormone treatment does not interfere with signal-induced proteolysis of a separate proteasome target, IkappaBalpha or ERalpha proteolysis induced by ICI182780. Using thyroid hormone as a tool to inhibit ERalpha proteolysis, we examined the effect of loss of this regulatory function on estrogen-induced transcriptional responses. Consistent with earlier reports, estrogen activation of an idealized estrogen response element reporter gene was inhibited. However, thyroid hormone did not prevent induction of prolactin gene expression or the ability of ERalpha to stimulate proliferation. These results demonstrate that estrogen-induced proteolysis of ERalpha is not a general requirement for receptor transcriptional activation function, and they demonstrate that proteolytic regulation is a means by which other endocrine factors can indirectly modulate ERalpha activity.